XSpray Pharma AB (STU:6XP) Cash And Cash Equivalents : €18.10 Mil (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is XSpray Pharma AB Cash And Cash Equivalents?

XSpray Pharma AB's quarterly cash and cash equivalents declined from Jun. 2024 (€11.21 Mil) to Sep. 2024 (€6.59 Mil) but then increased from Sep. 2024 (€6.59 Mil) to Dec. 2024 (€18.10 Mil).

XSpray Pharma AB's annual cash and cash equivalents increased from Dec. 2022 (€10.93 Mil) to Dec. 2023 (€14.87 Mil) and increased from Dec. 2023 (€14.87 Mil) to Dec. 2024 (€18.10 Mil).

XSpray Pharma AB Cash And Cash Equivalents Historical Data

The historical data trend for XSpray Pharma AB's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XSpray Pharma AB Cash And Cash Equivalents Chart

XSpray Pharma AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Cash And Cash Equivalents

Get a 7-Day Free Trial

32.00

26.47

10.93

14.87

18.10

XSpray Pharma AB Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Cash And Cash Equivalents	Get a 7-Day Free Trial															14.87	9.20	11.21	6.59	18.10

XSpray Pharma AB Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

XSpray Pharma AB (STU:6XP) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

XSpray Pharma AB Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of XSpray Pharma AB's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

XSpray Pharma AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XSpray Pharma AB (STU:6XP) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

XSPRAY:Sweden 0GHZ:UK

Address

Scheeles vag 2, Solna, SWE, SE-171 65

Website

https://www.xspraypharma.com

XSpray Pharma AB is a pharmaceutical company focused on developing improved PKIs for cancer treatment, leveraging its proprietary HyNap technology platform. The company aims to enhance clinical outcomes for cancer patients by improving the efficacy, safety, and patient experience of existing cancer therapies. Its product portfolio includes Dasynoc and other product candidates in different stages of development such as XS003 nilotinib, XS008 axitinib, and other.

XSpray Pharma AB Headlines

No Headlines